Neurologia最新文献_第2页

Consenso de expertos españoles sobre el uso de levodopa inhalada para el tratamiento de las fluctuaciones en la enfermedad de Parkinson 西班牙专家关于使用吸入左旋多巴治疗帕金森氏症挥发性疾病的共识

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-04-07 DOI: 10.1016/j.nrl.2026.502040

J. Pagonabarraga, M. Blázquez-Estrada, E. Freire-Álvarez, L. López-Manzanares, N. López-Ariztegui, Á. Sánchez-Ferro, D. Santos-García

{"title":"Consenso de expertos españoles sobre el uso de levodopa inhalada para el tratamiento de las fluctuaciones en la enfermedad de Parkinson","authors":"J. Pagonabarraga, M. Blázquez-Estrada, E. Freire-Álvarez, L. López-Manzanares, N. López-Ariztegui, Á. Sánchez-Ferro, D. Santos-García","doi":"10.1016/j.nrl.2026.502040","DOIUrl":"10.1016/j.nrl.2026.502040","url":null,"abstract":"<div><h3>Introduction</h3><div>The majority of Parkinson's disease (PD) patients undergoing treatment with levodopa (LD)—the first-line therapy for motor manifestations in PD—experience OFF episodes, characterized by symptom exacerbation. Inhaled LD is an on-demand therapy aimed at managing OFF episodes.</div></div><div><h3>Methods</h3><div>A scientific committee comprising six PD experts developed statements regarding inhaled LD based on evidence and their clinical practice experience. Using a two-round Delphi study, these statements were evaluated on a Likert scale ranging from 1 (completely disagree) to 9 (completely agree) by a panel of Spanish neurologists specializing in the management of PD patients. Consensus was considered achieved if ≥66.67% of responses fell within the same tertile as the median response for each statement ([1-3] disagreement, [4-6] neutral, [7-9] agreement).</div></div><div><h3>Results</h3><div>Forty-four statements across six thematic areas were developed. A total of 48 experts were invited to participate in the Delphi study, with participation rates of 91.7% in the first round and 83.3% in the second. After two rounds, consensus was reached in agreement on 40 out of 44 statements (91%). There was a high degree of expert consensus on the utility of inhaled LD for the rapid and reliable on-demand treatment of both motor and non-motor fluctuations in PD patients.</div></div><div><h3>Conclusions</h3><div>Inhaled LD was deemed a useful, effective, and safe on-demand treatment for OFF episodes in PD.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 7","pages":"Article 502040"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148859269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chinese identical twins with cerebrotendinous xanthomatosis: A family report and literature review 中国同卵双胞胎脑腱黄瘤病：一个家庭报告和文献复习

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-07-24 DOI: 10.1016/j.nrl.2025.501941

Y. Niu, S. Zhao, Y. Wang, Y. Zhang, Q. Weng

引用次数: 0

La transición de pacientes con enfermedades neuromusculares: recomendaciones de la Sociedad Española de Neurología Pediátrica y la Sociedad Española de Neurología. Avalado por la SENEP, la SEN y ASEM 神经肌肉疾病患者的过渡：西班牙儿科神经学会和西班牙神经学会的建议。由SENEP、SEN和ASEM支持

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-04-15 DOI: 10.1016/j.nrl.2026.502036

M. Álvarez-Molinero, J. Sotoca, L. Carrera-García, J. Alonso-Pérez, I. Martí-Carrera, I. Pitarch-Castellano, F. Munell, G. Morís, A. Camacho-Salas

{"title":"La transición de pacientes con enfermedades neuromusculares: recomendaciones de la Sociedad Española de Neurología Pediátrica y la Sociedad Española de Neurología. Avalado por la SENEP, la SEN y ASEM","authors":"M. Álvarez-Molinero, J. Sotoca, L. Carrera-García, J. Alonso-Pérez, I. Martí-Carrera, I. Pitarch-Castellano, F. Munell, G. Morís, A. Camacho-Salas","doi":"10.1016/j.nrl.2026.502036","DOIUrl":"10.1016/j.nrl.2026.502036","url":null,"abstract":"<div><h3>Introduction</h3><div>The increased survival of adolescent patients with neuromuscular disease (NMD) entails the transition of these patients to adult healthcare. The process of care transition seeks to guarantee the continuity of healthcare, although it is not always well planned. This consensus statement aims to provide a conceptual framework for the care transition of young patients with NMD.</div></div><div><h3>Methods</h3><div>A review of the literature on the subject was performed by NMD experts from the Spanish Society of Paediatric Neurology and the Spanish Society of Neurology, and a final consensus statement was drafted.</div></div><div><h3>Results</h3><div>The care transition of patients with NMD requires a multidisciplinary team including paediatric and adult care professionals from the different specialties involved, as well as central services and social workers. Paediatric and adult neurologists are the main physicians responsible for the patients, but a case manager is needed to coordinate the process and liaise with patients. Care transition should begin at the age of 12-14 years and involves 3 stages: preparation of the patient (including psychosocial considerations), transfer (when the patient is medically stable and prepared for the process), and integration (with post-transfer follow-up). The process should be evaluated using specific scales and questionnaires for patients and healthcare professionals.</div></div><div><h3>Conclusions</h3><div>Care transition is a complex process requiring proper planning and coordination between professionals to improve health outcomes and avoid losses to follow-up. Its effective implementation requires institutional backing.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 7","pages":"Article 502036"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148859274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cenobamato. Un nuevo fármaco que puede cambiar el concepto de epilepsia focal farmacorresistente Cenobamato。一种可能改变耐药局灶性癫痫概念的新药

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-04-06 DOI: 10.1016/j.nrl.2026.502033

J.J. Poza

{"title":"Cenobamato. Un nuevo fármaco que puede cambiar el concepto de epilepsia focal farmacorresistente","authors":"J.J. Poza","doi":"10.1016/j.nrl.2026.502033","DOIUrl":"10.1016/j.nrl.2026.502033","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite the constant approval of new antiseizure medications in recent years, the percentage of patients whose epilepsy is not fully controlled remains stable, at approximately 30%-40% of cases. This is because the newly approved drugs, despite providing benefits in terms of tolerability, ease of use, and reduction of pharmacokinetic interactions, have not achieved greater efficacy against seizures than previous drugs.</div></div><div><h3>Development</h3><div>Cenobamate has changed this scenario. Both in clinical trials and clinical practice series, it has achieved hitherto unseen seizure freedom rates in patients showing no response to 2 or more drugs. Its tolerability is similar to that of its predecessors. The most frequently reported adverse reactions include somnolence, dizziness, headache, fatigue, and diplopia. In general, they were mild or moderate in intensity, with a tendency to decrease with time. To avoid these as far as is possible, proper management of polymedication is important, especially in patients with a high pharmacological burden when cenobamate is introduced. Given its action mechanism, the most relevant pharmacodynamic interactions will involve other voltage-dependent sodium channels and benzodiazepines, especially clobazam.</div></div><div><h3>Conclusion</h3><div>Considering the response rates obtained, cenobamate may change the concept of drug-resistant epilepsy. Failure of any 2 drugs will no longer be sufficient to define this condition; rather, it will require failure of the most efficacious drug.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 7","pages":"Article 502033"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148859270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Demostración de alteraciones del drenaje venoso y perfusión cerebral en síndrome de Sturge-Weber tipo 3 de diagnóstico tardío 在诊断较晚的Sturge-Weber 3型综合征中显示静脉引流和脑灌注异常

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-01-20 DOI: 10.1016/j.nrl.2025.502009

I. García Díaz, E. Ortegón Aguilar, R. Díaz Manga, A. Rodríguez Reguera

引用次数: 0

Linguistic and cultural adaptation of the Barcelona-2 Test in 6 Latin American dialect variants 巴塞罗那-2测试在6个拉丁美洲方言变体中的语言和文化适应

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2026-04-07 DOI: 10.1016/j.nrl.2026.502037

J. Peña-Casanova, F. Diéguez-Vide, M. Jaén, L. Vinaixa, J. Cortaberría, T. Villaseñor, Y. Castro, L. García, C. Castillo, C. Dechent, A.V. Ferreira, E. Torrealba, N. Ocampo, A. Rocchini, L. Arévalo, Y. Godoy, A. Silva, the Latin American Barcelona Test Group

{"title":"Linguistic and cultural adaptation of the Barcelona-2 Test in 6 Latin American dialect variants","authors":"J. Peña-Casanova, F. Diéguez-Vide, M. Jaén, L. Vinaixa, J. Cortaberría, T. Villaseñor, Y. Castro, L. García, C. Castillo, C. Dechent, A.V. Ferreira, E. Torrealba, N. Ocampo, A. Rocchini, L. Arévalo, Y. Godoy, A. Silva, the Latin American Barcelona Test Group","doi":"10.1016/j.nrl.2026.502037","DOIUrl":"10.1016/j.nrl.2026.502037","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuropsychological tests must be adapted to local sociocultural realities. The Barcelona-2 test (TB-2) is a tool used in Spain and Hispanic America to perform a general neuropsychological assessment. The objective of this study was to develop versions of the TB-2 for six major dialects of Spanish-speaking Latin American countries, taking into account cross-cultural and cross-linguistic factors.</div></div><div><h3>Method</h3><div>Working documents consisting of sheets with three columns were established: original version, proposals for changes and justification of the proposals. The phonetic-prosodic aspect of the evaluation, which was controlled by local evaluators, was excluded. The documents were completed by at least two researchers for each dialect and subsequently agreed upon. The proposals were compared with the meanings of the Royal Spanish Academy and the Dictionary of Americanisms of the Association of Academies of the Spanish Language. The final versions were the subject of six acceptability studies.</div></div><div><h3>Results</h3><div>Versions have been established for 19 countries with 47 working documents for the Mexican, Caribbean, Central American, Andean, Austral, and Chilean TB-2 dialect varieties.</div></div><div><h3>Conclusions</h3><div>For the first time a neuropsychological test, initially developed in Catalan and Spanish, is simultaneously adapted to the six major Hispanic American dialects. These versions will avoid local interpretations and improvisations when administering the test in any Spanish-speaking territory. Administration to broad populations without and with cognitive impairment should allow for completing or modifying some of the changes and, perhaps, adjusting the score ranges.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 7","pages":"Article 502037"},"PeriodicalIF":2.8,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148859268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Síndrome long lasting autonomic symptoms with hemicranea (LASH), una entidad rara aún no reconocida 偏头痛长期自主症状症候群（LASH），一种罕见的、尚未发现的实体

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2025-11-29 DOI: 10.1016/j.nrl.2025.501949

J.L. Camacho-Velasquez, B.C. Lobo-Minuve, J.A. Garcia-Alhama

引用次数: 0

Construyendo una oportunidad ante el estado epiléptico mediante monitorización EEG y empleo de ketamina. Descripción de un caso clínico 通过脑电图监测和氯胺酮的使用，在癫痫状态前建立机会。临床病例描述

IF 2.8 4区医学

Neurologia Pub Date : 2026-09-01 Epub Date: 2025-12-05 DOI: 10.1016/j.nrl.2025.501951

Á. Juiz Fernández, X. Rodríguez Osorio, F.J. López González, P. Cacabelos Pérez

引用次数: 0

Manejo práctico de la terapia hipolipemiante en el ictus y ataque isquémico transitorio: consenso y recomendaciones prácticas 中风和暂时性缺血性中风低血脂治疗的实际管理：共识和实际建议

IF 2.8 4区医学

Neurologia Pub Date : 2026-07-01 Epub Date: 2026-05-20 DOI: 10.1016/j.nrl.2026.502076

M. Freijo-Guerrero, P. Cardona, M. Castellanos, R. de Torres-Chacón, A. Gil-Núñez, M. Guillán, P. Martínez-Sánchez, E.J. Palacio-Portilla, F. Purroy, T. Segura, J. Masjuan Vallejo

{"title":"Manejo práctico de la terapia hipolipemiante en el ictus y ataque isquémico transitorio: consenso y recomendaciones prácticas","authors":"M. Freijo-Guerrero, P. Cardona, M. Castellanos, R. de Torres-Chacón, A. Gil-Núñez, M. Guillán, P. Martínez-Sánchez, E.J. Palacio-Portilla, F. Purroy, T. Segura, J. Masjuan Vallejo","doi":"10.1016/j.nrl.2026.502076","DOIUrl":"10.1016/j.nrl.2026.502076","url":null,"abstract":"<div><h3>Background</h3><div>Stroke represents a major public health challenge in Spain, with approximately 120,000 cases per year and a significant impact on mortality, disability, and dependency. Elevated LDL cholesterol (LDL-C) is a key modifiable causal factor in preventing vascular recurrences. This consensus statement aims to provide a comprehensive framework for the practical management of lipid-lowering therapy in patients with stroke or transient ischemic attack (TIA).</div></div><div><h3>Methods</h3><div>A panel of experts in neurology, specialized in the management of patients with stroke/TIA, participated in three sessions to review the updated evidence. Then, they reached a consensus on practical recommendations for the management of lipid-lowering therapy based on data from clinical trials, meta-analyses, and current clinical guidelines.</div></div><div><h3>Conclusions</h3><div>Reaching the therapeutic targets for LDL-C is essential to prevent recurrences in patients with stroke/TIA. To ensure a comprehensive management of LDL-C in patients with stroke/TIA, it is recommended to apply intensive therapeutic strategies, individualized approaches and a robust continuity of care to optimize secondary prevention. Therapeutic planning at discharge, neurologist-led risk factor control, and coordinated continuity of care between hospital and primary care settings are essentials for achieving long-term outcomes. Inclisiran has emerged as a new key therapy to enhance lipid control and improve treatment adherence in these patients, in alignment with national and international recommendations for achieving therapeutic targets and reducing the burden of vascular disease. Optimal implementation of this therapeutic approach may substantially contribute to improving the prognosis of patients with stroke/TIA.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 6","pages":"Article 502076"},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148573368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilización de recursos de atención médica relacionados con la migraña en el mundo real: un análisis de una base de datos administrativa en Colombia 现实世界中偏头痛相关医疗保健资源的使用：对哥伦比亚行政数据库的分析

IF 2.8 4区医学

Neurologia Pub Date : 2026-07-01 Epub Date: 2026-02-09 DOI: 10.1016/j.nrl.2025.502008

F. Sobrino, M. Zorro, M.T. Bedoya, M.L. Ramos

{"title":"Utilización de recursos de atención médica relacionados con la migraña en el mundo real: un análisis de una base de datos administrativa en Colombia","authors":"F. Sobrino, M. Zorro, M.T. Bedoya, M.L. Ramos","doi":"10.1016/j.nrl.2025.502008","DOIUrl":"10.1016/j.nrl.2025.502008","url":null,"abstract":"<div><h3>Introduction</h3><div>Migraine is a chronic condition characterized by recurrent episodes of severe headache, significantly affecting the functionality of the individuals. The global prevalence and the impact on the quality of life highlight the need for research on its epidemiology and management, especially in specific context such as Colombia, where information on the subject is scarce.</div></div><div><h3>Methods</h3><div>A retrospective descriptive study was conducted with data from the Information System for Social Protection in Colombia (SISPRO) between 2027 and 2021, evaluating the incidence, prevalence, treatment pattern and cost associated with migraine management.</div></div><div><h3>Results</h3><div>293,028 incident cases and 1,711,794 prevalent cases of migraine were identified with a higher incidence and prevalence in women. The use of prophylactic treatments and visits to neurology showed an increasing trend. Although pharmaceutical costs represented the greatest economic burden, they decreased over the course of the study. The annual healthcare cost per patient, expressed in Purchasing Power Parity (PPP) decreased from PPP$110 in 2017 to a minimum of PPP$39 in 2019. The annual pharmacy cost per patient also dropped from PPP$115 in 20</div><div>17 to PPP$64 in 2019.</div></div><div><h3>Conclusions</h3><div>This study highlights migraine as a common condition in Colombia, with a prevalence and management that reflect a need for improved educational and treatment strategies. The research also highlights the importance of national data in understanding and addressing this condition, suggesting the need for public health policies focused on the prevention and optimized management of migraine.</div></div>","PeriodicalId":19300,"journal":{"name":"Neurologia","volume":"41 6","pages":"Article 502008"},"PeriodicalIF":2.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148573370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0